Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Sep 14,2022
Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"
On the afternoon of August 30, 2022, Shanghai Enterprise Confederation, Shanghai Entrepreneurs Association, Shanghai Economic Organization Federation and Jiefang Daily jointly held a press conference for the 2022 Shanghai Top 100 Enterprises in the China Financial Information Center.
More
Medicilon was selected as "2022 Shanghai Top 100 Emerging Industry Enterprises" and "2022 Shanghai Top 100 Growth Enterprises"
Sep 01,2022
Medicilon has been approved as the first batch of Group Open Innovation (GOI) for large enterprises in Pudong in 2022
Shanghai Medicilon Inc. was invited to attend the GOI press conference. The Medicilian Academician Innovative Drug Maturation Center was selected as the 2022 Pudong Large Enterprise Open Innovation Center.
More
Medicilon has been approved as the first batch of Group Open Innovation (GOI) for large enterprises in Pudong in 2022
Aug 29,2022
Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use
On August 8, 2022, Cullgen Inc announced the approval of the IND application for a TRK degrader (CG001419) for the treatment of advanced solid tumors. CG001419 is the world's first in class TRK (neurotrophic factor receptor tyrosine kinase) protein degrader.
More
Medicilon Assists | Cullgen's class 1 new drug TRK degrader CG001419 was approved for clinical use
Aug 15,2022
Medicilon was awarded the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022"
Recently, the SMDC released the list of the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022". With its strong scientific and technological innovation strength, Shanghai Medicilon Inc. stands out from many outstanding enterprises and ranks among the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022".
More
Medicilon was awarded the "Top 100 Listed Companies on the Sci-Tech Innovation Board in 2022"
Aug 15,2022
Medicilon is listed in the 2022 China Biopharmaceutical Industry Value List "Top 20 Most Influential CXO Enterprises"
On August 4, 2022, the 6th China Bio-Pharma Partnering Forum 2022 and the 2022 China Biomedical Industry Value List Award Ceremony was held, Shanghai Medicilon Inc. was on the list of the "Top 20 Most Influential CXO Enterprise."
More
Medicilon is listed in the 2022 China Biopharmaceutical Industry Value List "Top 20 Most Influential CXO Enterprises"
Aug 01,2022
Medicilon has been listed in the 2021 "Top 20 CXO (including CDMO) Enterprises in China" for 4 consecutive years
On July 12, the 2021 "Top 20 CXO (including CDMO) Enterprise in China" selected by Menet was officially released, which once again demonstrated the professionalism and influence of a strong enterprises in China's pharmaceutical industries.
More
Medicilon has been listed in the 2021 "Top 20 CXO (including CDMO) Enterprises in China" for 4 consecutive years
Jul 11,2022
Medicilon and BravoBio have reached a strategic collaboration on innovative vaccine IND R&D services
On June 28, 2022, Shanghai Medicilon Inc. (Medicilon) and Shanghai BravoBio Co. Ltd. (BravoBio) signed a strategic collaboration agreement online to officially become the collaboration partner.
More
Medicilon and BravoBio have reached a strategic collaboration on innovative vaccine IND R&D services
Jul 11,2022
To assist preclinical research of RNA drugs, Medicilon and Acon Pharmaceuticals reached a strategic collaboration
On June 24, 2022, Shanghai Medicilon Inc. (Medicilon) and ACON Pharmaceuticals Inc. (ACON) reached a strategic collaboration.
More
To assist preclinical research of RNA drugs, Medicilon and Acon Pharmaceuticals reached a strategic collaboration
Jul 11,2022
Empowering gene therapy, Medicilon and ZY Therapeutics reach a strategic collaboration
On June 28, 2022, Medicilon and ZY Therapeutics signed a strategic collaboration on preclinical IND application services to jointly promote development of gene therapy drugs.
More
Empowering gene therapy, Medicilon and ZY Therapeutics reach a strategic collaboration
Jul 04,2022
Medicilon and Suzhou Langrui have reached a strategic collaboration
On June 19, 2022, Shanghai Medicilon Inc. and Suzhou Langrui Biomedical Co., Ltd. signed a strategic collaboration agreement on innovative drug research and development services.
More
Medicilon and Suzhou Langrui have reached a strategic collaboration
Jul 04,2022
Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use
On June 10, 2022, Bio-Thera Solutions, Ltd. (Bio-Thera) announced that BAT2022 for injection has obtained a clinical trial approval.
More
Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use
Jul 04,2022
Medicilon reached the strategic collaboration on preclinical IND application services with Welman Pharmaceutical & Mingyu New Drug
On June 23, 2022, Shanghai Medicilon Inc.,Welman Pharmaceutical and Shenzhen Mingyu New Drug Research and Development Co., Ltd. signed a strategic collaboration on preclinical IND application services.
More
Medicilon reached the strategic collaboration on preclinical IND application services with Welman Pharmaceutical & Mingyu New Drug